Intralytix Awarded Patent by USPTO for Bacteriophage Treatment of Colonization by Pathogenic Bacteria, Including MRSA
12/9/2008 2:05:09 PM
BALTIMORE--(BUSINESS WIRE)--Intralytix, Inc., announced today that it has been issued a patent by the U.S. Patent & Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection in persons colonized with pathogenic bacteria including MRSA. The patent broadly relates to the administration of compositions containing bacteriophages to individuals colonized with pathogenic bacteria in order to prevent the development of bacterial infections. The claims cover the general method, means and routes of administration, and specific cases including MRSA.
comments powered by